ArticleJournal of gastrointestinal cancer2026
The Global Landscape of Colorectal cancer Incidence and Mortality in 2022 and Projections to 2045: New Estimates From GLOBOCAN 2022.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Serum inflammatory markers and influencing factors in patients with colorectal adenomas.American journal of cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC), ranking as the third most common cancer globally, poses a serious public health threat. Updated assessment of its geographic and temporal burden is crucial to understand evolving risk factors and CRC control strategy efficacy.
methodsData on CRC incidence and mortality in 2022 were extracted from the GLOBOCAN database. Age-standardized Incidence/Mortality rates (ASIRs/ASMRs) were calculated by sex, country, and region. Burden estimates by age group and CRC subsites were derived, and future projections for 2045 were modeled using global population forecasts.
resultsIn 2022, an estimated 1,926,425 new CRC cases and 904,019 deaths occurred globally. CRC cases comprise 59.3% colon cancer, 37.9% rectal cancer, and 2.8% anal cancer. Age-specific analysis revealed that although the highest ASIR and ASMR were both observed in individuals aged ≥ 85 years (232.6 and 192.3 per 100,000, respectively), the highest number of CRC cases occurred in the 60-69 age group. East Asia accounted for 36.33% of global cases, with China alone contributing 26.84%. The highest ASIRs were observed in Australia/New Zealand (35.3 per 100,000), Europe (30.5), and North America (27.2), while the lowest ASIR was in Africa and South Asia. ASMRs mirrored the geographic patterns of ASIR, with Eastern Europe having the highest ASMRs (19.6 per 100,000 males) and South Asia the lowest (2.5 per 100,000 females). Moreover, rising CRC rates in transitioning economies and younger populations were noted. By 2045, the global CRC burden is projected to reach 3.28 million new cases and 1.66 million deaths, predominantly in very high and high Human Development Index (HDI) countries.
conclusionWith the population aging and changing lifestyles, the burden of CRC is expected to increase, underscores the urgent need for targeted interventions, enhanced global surveillance, early screening programs, and precision prevention strategies to mitigate future incidence and mortality.
Indexed as
Identifiers
41973170What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.